{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:43:02Z","timestamp":1768272182912,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HR21C0198"],"award-info":[{"award-number":["HR21C0198"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bbrc.2022.09.104","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:09:29Z","timestamp":1664492969000},"page":"85-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Generation of genetically engineered mice for lung cancer with mutant EGFR"],"prefix":"10.1016","volume":"632","author":[{"given":"Da-Som","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wonjun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyungtaek","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chae Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joongkee","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Cheol","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-0259","authenticated-orcid":false,"given":"Jae Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-9883","authenticated-orcid":false,"given":"Young Hoon","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-0099","authenticated-orcid":false,"given":"Jin Kyung","family":"Rho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2022.09.104_bib1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.09.104_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.15252\/embr.201439949","article-title":"Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure","volume":"16","author":"Pagliarini","year":"2015","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbrc.2022.09.104_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fphar.2013.00053","article-title":"A\u00a0view on EGFR-targeted therapies from the oncogene-addiction perspective","volume":"4","author":"Perez","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ctrv.2011.10.003","article-title":"EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects","volume":"38","author":"Soria","year":"2012","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2022.09.104_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2006.04.022","article-title":"The impact of human EGFR kinase domain mutations on lung tumorigenesis and in\u00a0vivo sensitivity to EGFR-targeted therapies","volume":"9","author":"Ji","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2022.09.104_bib8","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.104_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.09.104_bib11","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbrc.2022.09.104_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2008.05.017","article-title":"Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line","volume":"63","author":"Rho","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbrc.2022.09.104_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2022.09.104_bib14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2022.09.104_bib15","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.bbrc.2022.09.104_bib16","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib17","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.104_bib18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-16-1773","article-title":"Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer","volume":"23","author":"Khozin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.104_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.09.104_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2022.09.104_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2022.09.104_bib22","article-title":"Patterns and treatment strategies of osimertinib resistance in T790M-positive non-small cell lung cancer: a pooled analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101999","article-title":"Cellular origins of EGFR-driven lung cancer cells determine sensitivity to therapy","volume":"8","author":"Chen","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbrc.2022.09.104_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11523-018-0568-z","article-title":"Discovery of a potent and mutant-selective EGFR inhibitor that overcomes T790M-mediated resistance in lung cancer","volume":"13","author":"Kim","year":"2018","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1158\/0008-5472.CAN-16-2432","article-title":"Superior efficacy and selectivity of novel small-molecule kinase inhibitors of T790M-mutant EGFR in preclinical models of lung cancer","volume":"77","author":"Rho","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.104_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nn.2467","article-title":"A\u00a0robust and high-throughput Cre reporting and characterization system for the whole mouse brain","volume":"13","author":"Madisen","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbrc.2022.09.104_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbrc.2022.09.104_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1101\/gr.163394.113","article-title":"Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases","volume":"24","author":"Sung","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.bbrc.2022.09.104_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In\u00a0vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2022.09.104_bib30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2022.09.104_bib31","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2022.09.104_bib32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2022.09.104_bib33","first-page":"OF1","author":"Choi","year":"2022"},{"key":"10.1016\/j.bbrc.2022.09.104_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/cancers7020763","article-title":"Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer","volume":"7","author":"Isozaki","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2022.09.104_bib35","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.cllc.2021.06.011","article-title":"Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature","volume":"23","author":"Koopman","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbrc.2022.09.104_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib37","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3747\/co.25.3760","article-title":"ALK inhibitors, resistance development, clinical trials","volume":"25","author":"Rothenstein","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib38","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/j.cllc.2019.06.007","article-title":"ROS1-rearranged NSCLC with secondary resistance mutation: case report and current perspectives","volume":"20","author":"Guisier","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbrc.2022.09.104_bib39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.bbrc.2022.09.104_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22013663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X22013663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:44:48Z","timestamp":1762094688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X22013663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S0006291X22013663"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.09.104","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation of genetically engineered mice for lung cancer with mutant EGFR","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2022.09.104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}